Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Shareholder Alert: Robbins LLP Announces Another Complaint Filed Against Aclaris Therapeutics, Inc. (ACRS)

November 21, 2019 GMT

SAN DIEGO & WAYNE, Pa.--(BUSINESS WIRE)--Nov 21, 2019--

Shareholder rights law firm Robbins LLP announces that a purchaser of Aclaris Therapeutics, Inc. (NASDAQ: ACRS) filed a derivative complaint against the company’s officers and directors for breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and alleged violations of the Securities Exchange Act of 1934 from May 8, 2018 through the present. Aclaris, a pharmaceutical company, identifies, develops, and commercializes therapies for dermatological and immune-inflammatory diseases. Its lead product is ESKATA, a hydrogen peroxide topical solution that treats seborrheic keratosis.

If you suffered a loss as a result of Aclaris’ misconduct, click here.

Aclaris Therapeutics (ACRS) Accused of Making Misleading Claims Regarding its ESKATA Drug

According to the complaint, in May 2018, Aclaris announced the launch of ESKATA, touting the product as the “first and only FDA-approved topical treatment for seborrheic keratosis.” Despite positive expectations, Aclaris acknowledged in its 2017 10-K that ESKATA was subject to post-marketing restrictions and that failure to comply with regulations could lead to penalties. Despite these warnings, Aclaris’ officers and directors allowed advertisements for ESKATA that exaggerated the drug’s efficacy and understated its risks. Consequently, on June 20, 2019, the FDA issued a letter that expressed concern over misleading statements and omissions in Aclaris’ advertising regarding ESKATA’s efficacy and risk of harmful side effects, noting that the Company had already been warned about the consequences of these advertising defects prior to publishing. As a result of Aclaris’ officers and directors’ misconduct, Aclaris, its CEO, and its CFO have been named in two federal securities class action lawsuits, which could further deplete the Company’s assets. Since this news, Aclaris’ share price has fallen $3.35, an almost 66% decline from its June 19, 2019 closing price of $5.11.

Contact us to learn more:

Leo Kandinov
(800) 350-6003
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

View source version on businesswire.com:https://www.businesswire.com/news/home/20191121005758/en/

CONTACT: Leo Kandinov

Robbins Arroyo LLP

5040 Shoreham Place

San Diego, CA 92122


(619) 525-3990 or Toll Free (800) 350-6003





Copyright Business Wire 2019.

PUB: 11/21/2019 11:39 AM/DISC: 11/21/2019 11:39 AM